에 대한 최신 뉴스 Icon (NASDAQ:ICLR) 주식

Icon

Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical-device firms. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities. The company is headquartered in Ireland.

News

BILL

ETSY

ICLR

MTCH

SDRL

엘리엇 인베스트먼트 매니지먼트(Elliott Investment Management)는 3분기에 분주했다. 미 증권거래위원회(SEC)에 새로 제출한 13-F에 따르면 이 행동주의 투자자는 여행 및 숙박에 초점을 맞춘 여러 가지 새로운 포지션을 포함하여 여러 가지 포트폴리오 전환을 수행했다.

엘리엇이 3분기에 웨스턴 디지털, 엣시는 추가; 씨드릴, 블랙라인, NRG 에너지는 축소

Large Cap

Movers

Trading Ideas

이들 10개 대형주는 지난주 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 1. 아이콘(NASDAQ:ICLR)의 주식은 예상보다 저조한 실적을 발표한 후 25.95% 급락했다. 여러 애널리스트들도 주가 목표를 하향 조정했다.

제뉴인 파츠 및 탑빌드가 지난주 최악의 성과를 보인 10개 대형주 중 일부 (10월 21일-10월 25일)

Icon PLC

RBC Capital analyst Sean Dodge reiterates Icon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) with a Outperform and maintains $263 price target.

Price Target

Reiteration

Analyst Ratings

RBC Capital Reiterates Outperform on Icon, Maintains $263 Price Target

WIIM

ICON shares are trading lower after the company issued FY25 guidance with its midpoint below estimates.

Guidance

ICON Earlier Issued Guidance; Sees FY25 Revenue $8.05B-$8.65B vs $8.496B Est., Adj. EPS $13.00-$15.00 vs $14.83 Est.

Clinical research organization ICON plc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) announced its financial guidance for <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/b42971328/icon-issues-financial-guidance-for-full-year-2025" rel="noreferrer noopener">fiscal year 2025 on Tuesday</a>.
What Happened: The Dublin-based company forecasts revenues of $8.05 billion — $8.65 billion. This represents growth of about 1% at the midpoint compared to the <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">consensus of $8.5 billion</a>.
The company expects adjusted earnings per share to be in the range of $13 to $15. That&#8217;s flat over the full-year 2024 adjusted earnings per share guidance midpoint compared to the consensus of $14.83.
See Also: <a href="https://www.benzinga.com/25/01/42980742/trump-off-hook-in-2020-election-case-special-counsel-smith-says-evidence-was-sufficient-to-obtain-and-sustain-a-conviction">Trump&#8217;s 2024 Election Win Spares Him From &#8216;Conviction&#8217; In Jan. 6 Case, Special Counsel Says</a>
ICON CEO Steve Cutler says trial activity has been &#8220;impacted by cautious spending from biopharma customers in both the biotech and large pharma businesses.&#8221; 
The company&#8217;s outlook for this year reflects an expected transition period, which includes a headwind from its top two customers on a combined basis, coupled with &#8220;an inconsistent recovery in biotech,&#8221; he added.
For fiscal year 2024, the company reaffirmed its current guidance of revenue of $8.26 billion — $8.3 billion and adjusted EPS of $13.90 &#8211; $14.10 versus consensus of $8.28 billion and $13.98, respectively.
Why It Matters: William Blair analysts are &#8220;surprised by the size of the topline cut relative to management&#8217;s initial thoughts last quarter (anticipated revenue growth in the low to mid-single digits for this year).&#8221;
Analyst Max Smock expects the company to face challenges in understanding &#8220;cautious spending patterns&#8221; from biopharma clients, including Pfizer Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) and Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>).
There&#8217;s also uncertainty about when biotech demand will stabilize. Investors debate whether $14 or $15 per share was the right target for the quarter.
The initial guidance for next year will lean closer to $15, observers say. However, margins will face more pressure than expected.
Price Action: Icon stock is down 6.96% at $202.81 at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/42980720/microsoft-taps-meta-veteran-to-lead-new-coreai-division-plans-shift-from-openai-dependence" target="_blank" rel="noreferrer noopener">Microsoft Launches CoreAI Division: Ex-Meta Exec To Supercharge Copilot And AI Innovations</a></li>
</ul>
Image: Shutterstock

Analyst Color

Health Care

General

Clinical Research Firm ICON Faces Headwinds From Top Customers And Biotech Recovery Uncertainty

William Blair analyst Max Smock reiterates Icon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) from Outperform to Outperform.

William Blair Reiterates Outperform on Iconto Outperform

ICON Plc Released The Findings Of A Survey Of Over 120 Biotech And Pharma Professionals Developing Treatments For Neurodegenerative Disorders

Icon shares are trading higher after RBC Capital initiated coverage on the stock with an Outperform rating and announced a price target of $263.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Piper Sandler analyst Mike Lavery initiated coverage on The Coca-Cola Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KO#NYSE">KO</a>) with an Overweight rating and announced a price target of $74. Coca-Cola shares closed at $60.81 on Monday. <a href="https://www.benzinga.com/quote/KO/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Truist Securities analyst John McDonald initiated coverage on JPMorgan Chase &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>) with a Hold rating and announced a price target of $260. JPMorgan shares closed at $240.85 on Monday. <a href="https://www.benzinga.com/quote/JPM/analyst-ratings">See how other analysts view this stock.</a></li>
<li>RBC Capital analyst Sean Dodge initiated coverage on ICON Public Limited Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) with an Outperform rating and announced a price target of $263. Icon shares closed at $215.51 on Monday. <a href="https://www.benzinga.com/quote/ICLR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>UBS analyst Eliana Merle initiated coverage on Ascendis Pharma A/S (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) with a Buy rating and announced a price target of $196. Ascendis Pharma shares closed at $140.28 on Monday. <a href="https://www.benzinga.com/quote/ASND/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Cantor Fitzgerald analyst Ross Osborn initiated coverage on Anteris Technologies Global Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVR#NASDAQ">AVR</a>) with an Overweight rating and announced a price target of $9. Anteris Technologies shares closed at $5.61 on Monday. <a href="https://www.benzinga.com/quote/AVR/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying KO stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="486" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/07090849/image-35-1024x486.png" alt="" class="wp-image-721909" style="width:491px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/07090849/image-35-1024x486.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/07090849/image-35-300x142.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/07090849/image-35-768x364.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/07090849/image-35.png 1142w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/42839544/wells-fargo-gears-up-for-q4-print-here-are-the-recent-forecast-changes-from-wall-streets-most-accurate-analysts">Wells Fargo Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street&#8217;s Most Accurate Analysts</a></li>
</ul>

Initiation

Pre-Market Outlook

Markets

ASND

This Coca-Cola Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

RBC Capital analyst Sean Dodge initiates coverage on Icon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) with a Outperform rating and announces Price Target of $263.

RBC Capital Initiates Coverage On Icon with Outperform Rating, Announces Price Target of $263

Citigroup analyst Patrick Donnelly maintains Icon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) with a Buy and lowers the price target from $300 to $290.

Citigroup Maintains Buy on Icon, Lowers Price Target to $290

Truist Securities analyst Jailendra Singh reiterates Icon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) with a Buy and lowers the price target from $295 to $284.

Truist Securities Reiterates Buy on Icon, Lowers Price Target to $284

Barry will continue to report to ICON's Chief Executive Officer, Steve Cutler.

Management

ICON Appoints Barry Balfe As COO

Baird analyst Eric Coldwell maintains Icon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) with a Neutral and lowers the price target from $249 to $225.

Baird Maintains Neutral on Icon, Lowers Price Target to $225

Leerink Partners analyst Michael Cherny reiterates Icon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) with a Outperform and lowers the price target from $270 to $255.

Leerink Partners Reiterates Outperform on Icon, Lowers Price Target to $255

Elliott Investment Management was busy in the third quarter. According to a new <a href="https://www.sec.gov/Archives/edgar/data/1048445/000156761920019906/0001567619-20-019906-index.htm">13-F</a> filing with the SEC, the activist made several portfolio moves, with multiple new positions focused around <a href="https://www.benzinga.com/news/24/10/41417317/southwest-airlines-in-settlement-talks-with-activist-investor-elliott-management-to-avoid-proxy-figh">travel and lodging</a>.
Here are all of Elliott&#8217;s new positions from the third quarter:
<ul>
<li>Utilities Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>)</li>
</ul>
<ul>
<li>Arm Holdings Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>) call options</li>
</ul>
<ul>
<li>Texas Instruments Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXN#NASDAQ">TXN</a>) call options</li>
</ul>
<ul>
<li>Invesco QQQ Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) call options</li>
</ul>
<ul>
<li>Energy Select Sector SPDR Fund Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>) call options</li>
</ul>
<ul>
<li>Alaska Air Group Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALK#NYSE">ALK</a>) call options</li>
</ul>
<ul>
<li>American Airlines Group Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAL#NASDAQ">AAL</a>) call options</li>
</ul>
<ul>
<li>ICON Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) call options</li>
</ul>
<ul>
<li>IQVIA Holdings Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IQV#NYSE">IQV</a>) call options</li>
</ul>
<ul>
<li>Marriott International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAR#NASDAQ">MAR</a>) put options</li>
</ul>
<ul>
<li>Hilton Worldwide Holdings Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLT#NYSE">HLT</a>) put options</li>
</ul>
<ul>
<li>Equinix Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EQX#NASDAQ">EQX</a>) put options</li>
</ul>
<ul>
<li>Hyatt Hotels Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/H#NYSE">H</a>) put options</li>
</ul>
<ul>
<li>Materials Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLB#NYSE">XLB</a>) put options</li>
</ul>

Here&#8217;s a look at all of the positions Elliott increased during the third quarter:
<ul>
<li>Southwest Airlines Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUV#NYSE">LUV</a>) increased by 919%</li>
</ul>
<ul>
<li>Western Digital Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDC#NASDAQ">WDC</a>) increased by 90%</li>
</ul>
<ul>
<li>Etsy Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETSY#NASDAQ">ETSY</a>) increased buy 11%</li>
</ul>
<ul>
<li>Match Group, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTCH#NASDAQ">MTCH</a>) increased by 3%</li>
</ul>

Here are all of the positions Elliott trimmed during the quarter:
<ul>
<li>BILL Holdings, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BILL#NYSE">BILL</a>) decreased by 24%</li>
</ul>
<ul>
<li>BlackLine, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BL#NASDAQ">BL</a>) decreased by 20%</li>
</ul>
<ul>
<li>Seadrill Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SDRL#NYSE">SDRL</a>) decreased by 9%</li>
</ul>
<ul>
<li>NRG Energy Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRG#NYSE">NRG</a>) decreased by 7%</li>
</ul>
The above information does not include call or put options that were increased, trimmed or sold completely during the quarter. 
This information was gathered using comparison tools from <a href="https://13f.info/13f/000101359424000968/compare/000101359424000660">13f.info</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/hedge-funds/24/11/41995340/nelson-peltzs-trian-fund-management-reshaped-portfolio-ahead-of-presidential-election">Nelson Peltz&#8217;s Trian Fund Management Reshaped Portfolio Ahead Of Presidential Election</a></li>
</ul>
Photo: Pixabay.

Elliott Investment Management Adds To Southwest, Western Digital, Etsy, Match Group; Trims BILL Holdings, Seadrill, BlackLine, NRG Energy In Q3

Icon shares are trading higher. Truist Securities maintained a Buy rating on the stock.

Icon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) has outperformed the market over the past 15 years by 3.83% on an annualized basis producing an average annual return of 15.94%. Currently, Icon has a market capitalization of $18.20 billion. 
Buying $1000 In ICLR: If an investor had bought $1000 of ICLR stock 15 years ago, it would be worth $9,139.97 today based on a price of $220.47 for ICLR at the time of writing.
<h3>Icon's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730125812_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 15 Years Ago Would Be Worth $9,100 Today

Truist Securities analyst Jailendra Singh maintains Icon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) with a Buy and lowers the price target from $363 to $295.

Truist Securities Maintains Buy on Icon, Lowers Price Target to $295

These ten large-cap stocks were the worst performers in the last week. Are they in your portfolio?
<ol>
<li>ICON plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) shares plummeted 25.95% after the company reported <a href="https://www.benzinga.com//node/41500867" target="_blank" rel="noreferrer noopener">worse-than-expected results</a>. Several analysts also cut the <a href="https://www.benzinga.com/quote/iclr/analyst-ratings" target="_blank" rel="noreferrer noopener">price target on the stock</a>.</li>
<li>Genuine Parts Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPC#NYSE">GPC</a>) stock tumbled 20.21% after it reported mixed third-quarter results and cut its <a href="https://www.benzinga.com//node/41455012" target="_blank" rel="noreferrer noopener">FY24 EPS below estimates</a>. Multiple analysts cut the <a href="https://www.benzinga.com/quote/gpc/analyst-ratings" target="_blank" rel="noreferrer noopener">price target on the stock</a>.</li>
<li>Newmont Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEM#NYSE">NEM</a>) shares dipped 15.97% after the company reported <a href="https://www.benzinga.com//node/41503948" target="_blank" rel="noreferrer noopener">third-quarter financial results</a>. Analysts trimmed the <a href="https://www.benzinga.com/quote/nem/analyst-ratings" target="_blank" rel="noreferrer noopener">stock&#8217;s price target</a>.</li>
<li>Tenet Healthcare Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) stock lost 14.71% last week. Several healthcare stocks and hospital operators fell in possible sympathy with HCA Healthcare, which declined on Q3 earnings.</li>
<li>Universal Health Services, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UHS#NYSE">UHS</a>) stock fell 14.33% last week after the company reported <a href="https://www.benzinga.com//node/41530333" target="_blank" rel="noreferrer noopener">Q3 financial results</a>.</li>
<li>HCA Healthcare, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>) stock fell 12.51% after reporting <a href="https://www.benzinga.com//node/41544243" target="_blank" rel="noreferrer noopener">worse-than-expected Q3 financial results</a>. The company expects Hurricane Helene&#8217;s impact to continue in 2025.</li>
<li>TopBuild Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLD#NYSE">BLD</a>) stock lost 11.48% last week as homebuilding stocks <a href="https://www.benzinga.com//node/41317881" target="_blank" rel="noreferrer noopener">took a beating</a> due to Hurricane Milton&#8217;s impact.</li>
<li>Carlisle Companies Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CSL#NYSE">CSL</a>) fell 11.45% last week on <a href="https://www.benzinga.com//node/41529849" target="_blank" rel="noreferrer noopener">worse-than-expected Q3 performance</a>.</li>
<li>Teradyne, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TER#NASDAQ">TER</a>) stock declined 11.34% after it reported <a href="https://www.benzinga.com//node/41503363" target="_blank" rel="noreferrer noopener">third-quarter financial results</a>. Some analysts trimmed the <a href="https://www.benzinga.com/quote/ter/analyst-ratings" target="_blank" rel="noreferrer noopener">price target on the stock</a>.</li>
<li>Comfort Systems USA, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIX#NYSE">FIX</a>) stock declined 11.27% after the company reported <a href="https://www.benzinga.com//node/41530044" target="_blank" rel="noreferrer noopener">worse-than-expected Q3 sales results</a>.</li>
</ol>
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/24/10/41560908/tesla-li-auto-and-microstrategy-are-among-top-10-large-cap-gainers-last-week-oct-21-oct-25-are-the">Tesla, Li Auto And MicroStrategy Are Among Top 10 Large Cap Gainers Last Week (Oct 21-Oct 25): Are The Others In Your Portfolio?</a></li>
</ul>

Genuine Parts Company, Universal Health Services, And TopBuild Are Among Top 10 Large Cap Losers Last Week (Oct 21-Oct 25): Are The Others In Your Portfolio?

TD Cowen analyst Charles Rhyee maintains Icon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) with a Buy and lowers the price target from $369 to $285.

TD Cowen Maintains Buy on Icon, Lowers Price Target to $285

RBC Capital initiated coverage of Icon (ICLR) with an Outperform rating and $263 price target Icon is among the largest of the global contract rese...

Icon initiated with an Outperform at RBC Capital

ICON plc draws bullish views at RBC on attractive valuation

Analyst David Windley of Jefferies maintained a Buy rating on Icon (ICLR – Research Report), reducing the price target to $275.00. David Windley ha...

Icon's Strategic Measures and Partnerships Justify Buy Rating Amid Margin Challenges

Mawer Investment Management Q4 2024 Quarterly Update

Backs FY24 revenue view $8.26B-$8.3B, consensus $8.28B. The company said, "With respect to full year 2024, the company reaffirmed its current guida...

Icon backs FY24 adjusted EPS view $13.90-$14.10, consensus $13.97

Sees FY25 revenue $8.05B-$8.65B, consensus $8.5B. CEO Steve Cutler commented, "ICON (ICLR) continues to navigate dynamic clinical development marke...

Icon sees FY25 adjusted EPS $13.00-$15.00, consensus $14.93

ICON issues 2025 guidance, stock slides 8%

Michael Ryskin, an analyst from Bank of America Securities, maintained the Buy rating on Icon (ICLR – Research Report). The associated price target...

Buy Rating on Icon: Navigating Short-term Challenges with Strong Competitive Position and Strategic Initiatives

RBC Capital analyst Sean Dodge maintained a Buy rating on Icon (ICLR – Research Report) yesterday and set a price target of $263.00. The company's ...

Icon (ICLR) Receives a Buy from RBC Capital

In a report released yesterday, Elizabeth Anderson CFA from Evercore ISI maintained a Buy rating on Icon (ICLR – Research Report), with a price tar...

Icon (ICLR) Gets a Buy from Evercore ISI

ASHTF

ASHTY

ASMIY

ASML

ASMLF

ASMXF

AZNCF

BZLFF

BZLFY

CCDBF

CCLLF

CMPGF

CMPGY

CTSDF

FINGF

IAFNF

NONOF

STLJF

TMTNF

TROLB

TRRVF

TSMWF

WOLTF

WTKWY

Press Releases

The Law Offices of Frank R. Cruz Continues Investigation of ICON Public Limited Company (ICLR) on Behalf of Investors

INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of ICON Public Limited Company (ICLR) on Behalf of Investors

ICON Announces Appointment of Chief Operating Officer

ICON and Its Employees Celebrated for Excellence in the Field of Clinical Research

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Icon Public Limited Company. - ICLR

ICON plc to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Biomarker and Trial Optimisation Needed to Drive R&D Progress in Alzheimer's and Related Disorders – ICON Survey

ICON Issues Financial Guidance for Full Year 2025

RBC Capital

Citigroup

Truist Securities

Baird

Leerink Partners

엘리엇 인베스트먼트 매니지먼트(Elliott Investment Management)는 3분기에 분주했다. 미 증권거래위원회(SEC)에 새로 제출한 13-F에 따르면 이 행동주의 투자자는 <a href="https://www.benzinga.com/news/24/10/41417317/southwest-airlines-in-settlement-talks-with-activist-investor-elliott-management-to-avoid-proxy-figh">여행 및 숙박</a>에 초점을 맞춘 여러 가지 새로운 포지션을 포함하여 여러 가지 포트폴리오 전환을 수행했다.
여기 3분기에 엘리엇이 새로 취득한 모든 포지션이 있다:
<ul>
<li>Utilities Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>)</li>
</ul>
<ul>
<li>Arm 홀딩스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>) 콜 옵션</li>
</ul>
<ul>
<li>텍사스 인스트루먼트 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXN#NASDAQ">TXN</a>) 콜 옵션</li>
</ul>
<ul>
<li>Invesco QQQ Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) 콜 옵션</li>
</ul>
<ul>
<li>Energy Select Sector SPDR Fund Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>) 콜 옵션</li>
</ul>
<ul>
<li>알래스카 에어 그룹 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALK#NYSE">ALK</a>) 콜 옵션</li>
</ul>
<ul>
<li>아메리칸 항공 그룹 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAL#NASDAQ">AAL</a>) 콜 옵션</li>
</ul>
<ul>
<li>아이콘 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) 콜 옵션</li>
</ul>
<ul>
<li>아이큐비아 홀딩스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IQV#NYSE">IQV</a>) 콜 옵션</li>
</ul>
<ul>
<li>메리어트 인터내셔널 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAR#NASDAQ">MAR</a>) 풋 옵션</li>
</ul>
<ul>
<li>힐튼 월드와이드 홀딩스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLT#NYSE">HLT</a>) 풋 옵션</li>
</ul>
<ul>
<li>에퀴닉스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EQX#NASDAQ">EQX</a>) 풋 옵션</li>
</ul>
<ul>
<li>하얏트 호텔 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/H#NYSE">H</a>) 풋 옵션</li>
</ul>
<ul>
<li>Materials Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLB#NYSE">XLB</a>) 풋 옵션</li>
</ul>
3분기 동안 엘리엇이 늘린 모든 포지션을 살펴보겠다:
<ul>
<li>사우스웨스트 항공 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUV#NYSE">LUV</a>) 919% 증가</li>
</ul>
<ul>
<li>웨스턴 디지털 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDC#NASDAQ">WDC</a>) 90% 증가</li>
</ul>
<ul>
<li>엣시 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETSY#NASDAQ">ETSY</a>) 11% 증가</li>
</ul>
<ul>
<li>매치 그룹 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTCH#NASDAQ">MTCH</a>) 3% 증가</li>
</ul>
이번 분기에 엘리엇이 줄인 모든 포지션은 다음과 같다:
<ul>
<li>빌 홀딩스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BILL#NYSE">BILL</a>) 24% 감소</li>
</ul>
<ul>
<li>블랙라인 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BL#NASDAQ">BL</a>) 20% 감소</li>
</ul>
<ul>
<li>씨드릴 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SDRL#NYSE">SDRL</a>) 9% 감소</li>
</ul>
<ul>
<li>NRG 에너지 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRG#NYSE">NRG</a>) 7% 감소</li>
</ul>
위의 정보는 분기 동안 증가하거나 줄어들거나 완전히 매도된 콜 또는 풋 옵션을 포함하지 않았다.
이 정보는 <a href="https://13f.info/13f/000101359424000968/compare/000101359424000660">13f.info</a>의 비교 도구를 사용하여 수집되었습니다.
다음 읽기:
<ul>
<li><a href="https://www.benzinga.com/hedge-funds/24/11/41995340/nelson-peltzs-trian-fund-management-reshaped-portfolio-ahead-of-presidential-election">넬슨 펠츠의 트라이언 펀드 매니지먼트가 대선 전 포트폴리오를 재편성</a></li>
</ul>
사진: Pixabay.

이들 10개 대형주는 지난주 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
1. 아이콘(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>)의 주식은 <a href="https://www.benzinga.com//node/41500867" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">예상보다 저조한 실적</a>을 발표한 후 25.95% 급락했다. 여러 애널리스트들도 <a href="https://www.benzinga.com/quote/iclr/analyst-ratings" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">주가 목표</a>를 하향 조정했다.
2. 제뉴인 파츠(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPC#NYSE">GPC</a>)의 주식은 엇갈린 3분기 실적과 <a href="https://www.benzinga.com//node/41455012" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">예상보다 낮은 2024년 EPS</a>를 발표한 후 20.21% 하락했다. 여러 애널리스트들이 <a href="https://www.benzinga.com/quote/gpc/analyst-ratings" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">주가 목표</a>를 하향 조정했다.
3. 뉴몬트(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEM#NYSE">NEM</a>)의 주식은 <a href="https://www.benzinga.com//node/41503948" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">3분기 재무 실적</a>을 발표한 후 15.97% 하락했다. 애널리스트들은 <a href="https://www.benzinga.com/quote/nem/analyst-ratings" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">주가 목표</a>를 하향 조정했다.
4. 테넷 헬스케어(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>)의 주식은 지난주 14.71% 하락했다. 몇몇 헬스케어 주식과 병원 운영자들은 3분기 실적이 감소한 HCA 헬스케어에 동조세 가능성이 있었다.
5. 유니버셜 헬스 서비스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UHS#NYSE">UHS</a>)의 주식은 <a href="https://www.benzinga.com//node/41530333" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">3분기 재무 실적</a>을 발표한 후 지난주 14.33% 하락했다.
6. HCA 헬스케어(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>)의 주식은 <a href="https://www.benzinga.com//node/41544243" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">예상보다 저조한 3분기 재무 실적</a>을 발표한 후 12.51% 하락했다. 이 회사는 허리케인 헬렌의 영향이 2025년까지 지속될 것으로 예상하고 있다.
7. 탑빌드(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLD#NYSE">BLD</a>)의 주식은 허리케인 밀턴의 영향으로 주택 건설 주식이 <a href="https://www.benzinga.com//node/41317881" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">타격을 받은 후</a> 11.48% 하락했다.
8. 칼라일 컴퍼니(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CSL#NYSE">CSL</a>)의 주식은 <a href="https://www.benzinga.com//node/41529849" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">예상보다 저조한 3분기 실적</a> 발표 후 11.45% 하락했다.
9. 테라다인(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TER#NASDAQ">TER</a>)의 주식은 <a href="https://www.benzinga.com//node/41503363" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">3분기 재무 실적</a>을 발표한 후 11.34% 하락했다. 일부 애널리스트들은 <a href="https://www.benzinga.com/quote/ter/analyst-ratings" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">주가 목표</a>를 하향 조정했다.
10. 컴포트 시스템즈 USA(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIX#NYSE">FIX</a>)의 주식은 <a href="https://www.benzinga.com//node/41530044" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">예상보다 저조한 3분기 매출 실적</a>을 발표한 후 11.27% 하락했다.
추가로 읽어보세요:
<ul>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%ED%85%8C%EC%8A%AC%EB%9D%BC%EC%99%80-%EB%A6%AC-%EC%98%A4%ED%86%A0%EB%8A%94-%EC%A7%80%EB%82%9C%EC%A3%BC-%EC%B5%9C%EA%B3%A0-%EC%84%B1%EA%B3%BC%EB%A5%BC-%EB%B3%B4%EC%97%AC%EC%A4%80-10%EA%B0%9C-%EB%8C%80/" target="_blank" rel="noopener">테슬라와 리 오토는 지난주 최고 성과를 보여준 10개 대형주 중 일부 (10월 21일-10월 25일)</a></li>
</ul>
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요. 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

Icon

뉴스

에 대한 최신 뉴스 Icon (NASDAQ:ICLR) 주식

금요일, 11월 15, 2024

토요일, 10월 26, 2024

뉴스

파트너 / 기고자

벤징가 글로벌